Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomised, Open Label Phase II Study of Active Specific Immunotherapy With Racotumomab Versus Support Treatment in Patients With Advanced Non-small Cell Lung Cancer

NCT01240447 is registered in ClinicalTrials.gov with Laboratorio Elea Phoenix S.A. as lead sponsor.

NCT NCT01240447
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01240447 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomised, Open Label Phase II Study of Active Specific Immunotherapy With Racotumomab Versus Support Treatment in Patients With Advanced Non-small Cell Lung Cancer
Lead sponsor
Laboratorio Elea Phoenix S.A.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
June 30, 2014
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer